CIK 0002007919
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Inhibrx Biosciences, Inc.
Sign in to watch- Ticker
- INBX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 990613523
- Phone
- +1 858-795-4220
- Business address
- 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- S-3ASR Offering Registration Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market buy Chief Executive Officer bought 10,040 shares at an average $84.56 ($848,977)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at an average $99.88 ($998,784)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy Director bought 5,000 shares at $100.00 ($500,000)
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Open-market buy Director bought 5,000 shares at $100.00 ($500,000)
- 4 Open-market sale Director sold 1,500 shares at an average $109.03 ($163,543)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale Director sold 1,000 shares at an average $115.47 ($115,468)
- 144 Insider Sale of Securities
Page 1 of 9 · 162 filings